Immunopathogenesis of ovarian cancer

Minerva Medica

Volumn 100, Issue 5, 2009, Pages 357-370

  Thompson, M S ^a   Mok, S C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Microdissection; Outcome assessment; Ovarian neoplasms

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; COLLAGEN TYPE 4; CYCLOOXYGENASE 2; ELASTASE; GELATINASE B; HLA DR ANTIGEN; LAMININ; METALLOPROTEINASE; PLASMINOGEN ACTIVATOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STROMELYSIN 2; TUMOR NECROSIS FACTOR ALPHA; UROKINASE;

CANCER GROWTH; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; MICROENVIRONMENT; NONHUMAN; OVARY CANCER; OVULATION; REVIEW;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; CYTOKINES; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MACROPHAGES; MATRIX METALLOPROTEINASES; OVARIAN NEOPLASMS; PROGNOSIS; RISK FACTORS; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949529738     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Bell DA, Scully RE. Clinical perspective on borderline tumors of the ovary. Current Topics in Obstetrics and Gynecology: Elsevier Science Publishing Co., Inc; 1991. p. 119-33.
3. Gallion HH, van Nagell JR, Jr., Powell DF, Donaldson ES, Higgins RV, Kryscio RJ et al. Stage I serous papillary carcinoma of the endometrium. Cancer 1989;63:2224-8.
4. Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 2000;19:11-9.
5. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Ann Rev Pathol 2006;1:119-50.
6. Dougan M, Dranoff G. The immune response to tumors. Curr Protoc Immunol 2009; 20:11.
7. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
8. Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer 1971;28:89-98.
9. Penn I. Malignant tumors in organ transplant recipients. New York: Springer-Verlag; 1970.
10. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006;247:4-21.
11. Cramer DW, Liberman RF, Titus-Ernstoff L, Welch WR, Greenberg ER, Baron JA et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer 1999;81:351-6.
12. Melin A, Sparen P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 2006;21:1237-42.
13. Parazzini F, La Vecchia C, Negri E, Moroni S, dal Pino D, Fedele L. Pelvic inflammatory disease and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 1996;5:667-9.
14. Rosenblatt KA, Rosenshein NB. Mumps parotitis and ovarian cancer. Am J Obstet Gynecol 1984;149:472-4.
15. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-67.
16. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-7.
17. Bonello N, McKie K, Jasper M, Andrew L, Ross N, Braybon E et al. Inhibition of nitric oxide: effects on interleukin-1 beta-enhanced ovulation rate, steroid hormones, and ovarian leukocyte distribution at ovulation in the rat. Biol Reprod 1996;54:436-45.
18. Espey LL. Ovulation as an inflammatory reaction - a hypothesis. Biol Reprod 1980;22:73-106.
19. Espey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 1994;50:233-8.
20. Richards JS, Russell DL, Ochsner S, Espey LL. Ovulation: new dimensions and new regulators of the inflammatory-like response. Annu Rev Physiol 2002;64:69-92.
21. Huang JQ, Lathi RB, Lemyre M, Rodriguez HE, Nezhat CH, Nezhat C. Coexistence of endometriosis in women with symptomatic leiomyomas. Fertil Steril 2009.
22. Nezhat C, Cho J, Morozov V, Yeung P, Jr. Preoperative periumbilical ultrasound-guided saline infusion (PUGSI) as a tool in predicting obliterating subumbilical adhesions in laparoscopy. Fertil Steril 2009;91:2714-9.
23. Morikawa H, Okamura H, Takenaka A, Morimoto K, Nishimura T. Histamine concentration and its effect on ovarian contractility in humans. Int J Fertil 1981;26:283-6.
24. Brannstrom M, Pascoe V, Norman RJ, McClure N. Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle. Fertil Steril 1994;61:488-95.
25. Takaya R, Fukaya T, Sasano H, Suzuki T, Tamura M, Yajima A. Macrophages in normal cycling human ovaries; immunohistochemical localization and characterization. Hum Reprod 1997;12:1508-12.
26. Wicherek L, Dutsch-Wicherek M, Galazka K, Banas T, Popiela T, Lazar A et al. Comparison of RCAS1 and metallothionein expression and the presence and activity of immune cells in human ovarian and abdominal wall endometriomas. Reprod Biol Endocrinol 2006;4:41.
27. Burke JM, Carroll DJ, Rowe KE, Thatcher WW, Stormshak F. Intravascular infusion of lipid into ewes stimulates production of progesterone and prostaglandin. Biol Reprod 1996;55:169-75.
28. Nash MA, Ferrandina G, Gordinier M, Loercher A, Freedman RS. The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer 1999;6:93-107.
29. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002;12:113-20.
30. Curry TE, Jr., Mann JS, Huang MH, Keeble SC. Gelatinase and proteoglycanase activity during the periovulatory period in the rat. Biol Reprod 1992;46:256-64.
31. Brannstrom M, Enskog A. Leukocyte networks and ovulation. J Reprod Immunol 2002;57:47-60.
32. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137-46.
33. Radisky DC, Stallings-Mann M, Hirai Y, Bissell MJ. Single proteins might have dual but related functions in intracellular and extracellular microenvironments. Nat Rev Mol Cell Biol 2009;10:228-34.
34. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007;121:2381-6.
35. Naylor MS, Malik ST, Stamp GW, Jobling T, Balkwill FR. In situ detection of tumour necrosis factor in human ovarian cancer specimens. Eur J Cancer 1990;26:1027-30.
36. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993;91:2194-206.
37. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006;42:745-50.
38. Takeyama H, Wakamiya N, O'Hara C, Arthur K, Niloff J, Kufe D, Sakarai K et al. Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res 1991;51:4476-80.
39. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993;53:1939-44.
40. Murdoch WJ, Van Kirk EA, Murdoch J. Plasmin cleaves tumor necrosis factor alpha exodomain from sheep follicular endothelium: implication in the ovulatory process. Biol Reprod 1999;60:1166-71.
41. Murdoch WJ, Colgin DC, Ellis JA. Role of tumor necrosis factor-alpha in the ovulatory mechanism of ewes. J Anim Sci 1997;75:1601-5.
42. Yang WL, Godwin AK, Xu XX. Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk. Cancer Res 2004;64:1534-40.
43. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR et al. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 2009;11:529-41.
44. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Müller-Holzner E et al. Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 1996;67:826-30.
45. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 2001;98:1176-81.
46. Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 2003;98:2607-23.
47. Aung PP, Oue N, Mitani Y, Nakayama H, Yoshida K, Noguchi T et al. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 2006;25:2546-57.
48. Rechardt O, Elomaa O, Vaalamo M, Pääkkönen K, Jahkola T, Höök-Nikanne J et al. Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines. J Invest Dermatol 2000;115:778-87.
49. Krampert M, Bloch W, Sasaki T, Bugnon P, Rülicke T, Wolf E et al. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell 2004;15:5242-54.
50. Yang WL, Roland IH, Godwin AK, Xu XX. Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells. Oncogene 2005;24:7991-8002.
51. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 2005;65:2234-42.
52. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001;61:4961-5.
53. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005;65:10355-62.
54. Slot KA, de Boer-Brouwer M, Voorendt M, Sie-Go DM, Ghahremani M, Dorrington JH et al. Irregularly shaped inclusion cysts display increased expression of Ki67, Fas, Fas ligand, and procaspase-3 but relatively little active caspase-3. Int J Gynecol Cancer 2006;16:231-9.
55. Gusberg SB, Deligdisch L. Ovarian dysplasia. A study of identical twins. Cancer 1984;54:1-4.
56. Deligdisch L, Gil J. Characterization of ovarian dysplasia by interactive morphometry. Cancer 1989;63:748-55.
57. Bell DA, Scully RE. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994;73:1859-64.
58. Deligdisch L, Einstein AJ, Guera D, Gil J. Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Cancer 1995;76:1027-34.
59. Rae MT, Niven D, Ross A, Forster T, Lathe R, Critchley HO et al. Steroid signalling in human ovarian surface epithelial cells: the response to interleukin-1alpha determined by microarray analysis. J Endocrinol 2004;183:19-28.
60. Gubbay O, Guo W, Rae MT, Niven D, Langdon SP, Hillier SG. Inflammation-associated gene expression is altered between normal human ovarian surface epithelial cells and cell lines derived from ovarian adenocarcinomas. Br J Cancer 2005;92:1927-33.
61. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007;42:93-126.
62. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 2007;42:193-212.
63. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009;27:83-117.
64. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-46.
65. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
66. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004;10:4450-6.
67. Sato E, Olson SH, Ann J, Bundy B, Nishikawa H, Qian F et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
68. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-6.
69. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
70. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH et al. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 2008;14:7667-73.
71. Nelson BH. The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 2008;222:101-16.
72. Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol 2006;18:1591-602.
73. Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A et al. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci 2006;97:57-63.
74. Løvig T, Andersen SN, Thorstensen L, Diep CB, Meling GI, Lothe RA et al. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer 2002;87:756-62.
75. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 1995;82:155-65.
76. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-62.
77. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in anti-tumor immunity. Trends Immunol 2001;22:269-76.
78. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004;4:595-602.
79. Humphreys RE, Hillman GG, von Hofe E, Xu M. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy. Cell Mol Immunol 2004;1:180-5.
80. Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009;4:e6412.
81. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005;54:369-77.
82. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
83. Wolf D, Wolf AM, Rumpold H, Fiegl H, Zeimet AG, Muller-Holzner E et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326-31.
84. Dietl J, Engel JB, Wischhusen J. The role of regulatory T cells in ovarian cancer. Int J Gynecol Cancer 2007;17:764-70.
85. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-72.
86. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67:8900-5.
87. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-81.
88. Bristow RE, Baldwin RL, Yamada SD, Korc M, Karlan BY. Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer 1999;85:658-68.
89. Li X, Ye F, Chen H, Lu W, Wan X, Xie X. Human ovarian carcinoma cells generate CD4(+)CD25(+) regulatory T cells from peripheral CD4(+)CD25(-) T cells through secreting TGF-beta. Cancer Lett 2007;253:144-53.
90. Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005;65:5020-6.
91. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46.
92. Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009;14:1761-70.
93. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
94. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002;19:247-58.
95. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002;62:5069-75.
96. Jerrells TR, Dean JH, Richardson G, Cannon GB, Herberman RB. Increased monocyte-mediated cytostasis of lymphoid cell lines in breast and lung cancer patients. Int J Cancer 1979;23:768-76.
97. Mantovani A, Peri G, Polentarutti N, Bolis G, Mangioni C, Spreafico F. Effects on in vitro tumor growth of macrophages isolated from human ascitic ovarian tumors. Int J Cancer 1979;23:157-64.
98. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
99. Santini SM, Belardelli F. Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines. Stem Cells 2003;21:495-505.
100. Yu JL, Rak JW. Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res 2003;5:83-8.
101. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4:641-8.
102. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997;3:999-1007.
103. Gordinier ME, Zhang HZ, Patenia R, Levy LB, Atkinson EN, Nash MA et al. Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma. Clin Cancer Res 1999;5:2498-505.
104. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995;27:79-85.
105. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM. Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 1997;28:321-31.
106. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150:1723-34.
107. Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S et al. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 1995;95:2391-6.
108. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009;59:300-5.
109. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000;10:33-41.
110. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002;277:24584-93.
111. Sica A, Saccani A, Bottazzi B, Bernasconi S, Allavena P, Gaetano B et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol 2000;164:733-8.
112. Bernasconi S, Matteucci C, Sironi M, Conni M, Colotta F, Mosca M et al. Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int J Cancer 1995;60:300-7.
113. Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Hönig A, Häusler S et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 2008;180:7338-48.
114. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 2007;5:1015-30.
115. Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia 2008;10:1092-104.
116. Vanky F, Nagy N, Hising C, Sjovall K, Larson B, Klein E. Human ex vivo carcinoma cells produce transforming growth factor beta and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 1997;43:317-23.
117. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol 2001;80:245-53.
118. Mythreye K, Blobe GC. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A 2009;106:8221-6.
119. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E et al. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 2009;125:367-73.
120. Wall L, Burke F, Smyth JF, Balkwill F. The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo. Gynecol Oncol 2003;88:S149-51.
121. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005;175:1197-205.
122. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007;178:8183-94.
123. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007;110:4319-30.
124. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 2006;66:9535-42.
125. Duyndam MC, Hilhorst MC, Schluper HM, Verheul HM, van Diest PJ, Kraal G et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Pathol 2002;160:537-48.
126. Lewis CE, Leek R, Harris A, McGee JO. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol 1995;57:747-51.
127. Orre M, Rogers PA. Macrophages and microvessel density in tumors of the ovary. Gynecol Oncol 1999;73:47-50.
128. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
129. Lin KW, Jacek T, Jacek R. Dendritic cells heterogeneity and its role in cancer immunity. J Cancer Res Ther 2006;2:35-40.
130. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004;64:5535-8.
131. Melichar B, Savary C, Kudelka AP, Verschraegen C, Kavanagh JJ, Edwards CL et al. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998;4:799-809.
132. Wertel F, Polak G, Rolinski J, Barczynski B, Kotarski J. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer. Adv Med Sci 2006;51:174-7.
133. Wertel I, Barczynski B, Kotarski J. The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment. Front Biosci 2008;13:2177-90.
134. Eisenthal A, Polyvkin N, Bramante-Schreiber L, Misonznik F, Hassner A, Lifschitz-Mercer B. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 2001;32:803-7.
135. Ye F, Chen HZ, Xie X, Ye DF, Lu WG. Ovarian carcinoma cells effectively inhibit differentiation and maturation of dendritic cells derived from hematopoietic progenitor cells in vitro. Cancer Invest 2005;23:379-85.
136. Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ et al. Depletion of dendritic cells delays ovarian cancer progression by boosting anti-tumor immunity. Cancer Res 2008;68:7684-91.
137. Cioca DP, Deak E, Cioca F, Paunescu V. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells. J Immunother 2006;29:41-52.
138. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ et al. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601-9.
139. Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003;9:1517-27.
140. Tobiásová Z, Pospísilová D, Miller AM, Minárik I, Sochorová K, Spísek R et al. In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clin Immunol 2007;122:18-27.
141. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000;96:422-30.
142. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther 2009;9:677-88.